ACN Newswire
Read More

Young Fashion Designers’ Contest 2021 winners revealed

indie
6 minutes

HONG KONG, Sep 14, 2021 - (ACN Newswire via SEAPRWire.com) - Asia's leading fashion event CENTRESTAGE, organised by the Hong Kong Trade Development Council (HKTDC), concluded on 12 September with the 2021 Hong Kong Young Fashion Designers' Contest (YDC). Ten promising local designers showcased their creations at an eye-catching fashion show with celebrities Denis Kwok (aka 193) and Bonnie Wong (aka Ah Jeng) showing up as special guests to add to the celebratory atmosphere. Following the catwalk parade, a judging panel of industry professionals picked out three winners from a pool of 10 for the four YDC awards. Champion and winner of the Best Visual Presentation Award Cady Lee received a monetary reward together with a one-month overseas internship sponsored by Fang Brothers Knitting Ltd.Champion and Best Visual Presentation Award: Cady Lee. Design: "Emotion the Shift of the Self"The winners at YDC 2021 were as follows:- Champion and Best Visual Presentation Award: Cady Lee. Design: "Emotion the Shift of the Self"- Excellence Award: Toki Wong. Design: "Zoom Olympic"- My Favourite Collection Award: Topsy Yu. Design: "Morning Moon"Champion Cady Lee said her collection, "Emotion the Sh...

JCN Newswire
Read More

Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer’s Disease and Dementia at the 13th Clinical Trials on Alzheimer’s Disease Conference

ruth
3 minutes

TOKYO, Oct 28, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct a total of 7 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (Development Code: BAN2401), at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference to be held virtually from November 4 to 7, 2020.Regarding lecanemab, Eisai will conduct four oral presentations. The first oral presentation will cover clinical study design and initial screening results of the newly initiated Phase III clinical study AHEAD 3-45 for preclinical Alzheimer's disease (AD) patients. The second oral presentation will cover the latest analysis results on expression of amyloid-related imaging abnormalities-edema (ARIA-E) from the Phase II study (Study 201) conducted on early AD patients. The third oral presentation will cover changes in brain-Abeta amounts and preliminary analysis results on ARIA-E expression as observed in the first 12-month treatment period of the ongoing open-label extension (OLE) study of Study 201. The fourth oral presentation will cover baseline characteristics of currently enrolled subjects in the Phase I...